Vitreous surgery for traumatic macular holes

Retina

Volumn 19, Issue 5, 1999, Pages 410-413

  Amari, Fujio ^a   Ogino, Nobuchika ^b   Matsumura, Miyo ^c   Negi, Akira ^d   Yoshimura, Nagahisa ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kurihara Eye Hospital   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Traumatic macular holes; Vitreous surgery

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE INJURY; FEMALE; FOLLOW UP; HUMAN; MALE; RETINA MACULA HOLE; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 0033499502     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-199919050-00009     Document Type: Article

References (19)

1. Gass JD. Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol 1988;93:777-786.
2. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 1991;190: 654-659.
3. Wendel RT, Patel AC, Kelly NE, et al. Vitreous surgery for macular holes. Ophthalmology 1993;100:1607-1608.
4. Glaser BM, Michels RG, Kuppermann BD, et al. Transforming growth factor-β2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology 1992;99:1162-1173.
5. Orrellana J, Lieberman RM. Stage III macular hole surgery. Br J Ophthalmol 1993;77:555-558.
6. Lansing MB, Glaser BM, Liss H, et al. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 1993;100:868-872.
7. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor-β2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes: preliminary anatomic results of a multicenter prospective randomized study. Retina 1993;13:296-301.
8. De Bustros S. Vitrectomy for prevention of macular holes. Results of a randomized multicenter clinical trial. Ophthalmology 1994;101:1055-1060.
9. Ryan EH Jr, Gilbert HD. Results of surgical treatment of recent-onset full-thickness idiopathic macular holes. Arch Ophthalmol 1994;112:1545-1553.
10. Liggett PE, Skolik S, Horio B, et al. Human autologous serum for the treatment of full-thickness macular holes: a preliminary study. Ophthalmology 1995;102:1071-1076.
11. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995;233:549-554.
12. Freeman WR, Azen SP, Kim JW, et al. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. Arch Ophthalmol 1997;115:11-21.
13. Gass JDM. Stereoscopic Atlas of Macular Disease: Traumatic Retinopathy, 4th ed. St. Louis: CV Mosby, 1997:737-774.
14. Rubin JS, Glaser BM, Thompson JT, Sjaarda RN, Pappas SS, Murphy RP. Vitrectomy, fluid-gas exchange and transforming growth factor-beta-2 for the treatment of traumatic macular holes. Ophthalmology 1995;102:1840-1845.
15. Garcia-Arumi J, Corcostegui B, Cavero L, Sararols L. The role of vitreoretinal surgery in the treatment of posttraumatic macular hole. Retina 1997;17:372-377.
16. Thompson JT, Smiddy WE, Williams GA, et al. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology 1998;105:700-706.
17. Lewis JM, Park I, Ohji M, Saito, Tano Y. Diamond-dusted silicone cannula for epiretinal membrane separation during vitreous surgery. Am J Ophthalmol 1997;124:552-554.
18. Mizusawa Y, Itibe M, Yoshizawa T, Ando N. Clinical evaluation of traumatic macular holes. Jpn Rev Clin Ophthalmol 1996;90:790-792.
19. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 1995;119:48-54.